Schedule

SATURDAY, APRIL 20, 2013

7:00 AM
Continental Breakfast

7:45 AM
Welcome & Introductions
Michael H. Pillinger, MD • New York University Langone Medical Center; New York, NY

8:00 AM
Opening Lecture: Placebo Analgesia in Clinical Trials and Practice
Roland Staud, MD • University of Florida; Gainesville, FL

At the conclusion of this session participants should be able to:

  • recognize important factors modulating placebo analgesia
  • differentiate between classical conditional and expectations as they apply to patient treatment responses
  • recognize that patient responses to medications are always modulated to some degree by expectation/placebo effects, and adjust clinical practice such that patient treatment responses will be enhanced rather than diminished by placebo effects

8:45 – 10:15 AM
SESSION I: THE BIG THREE

Year in Review: Lupus
Elena M. Massarotti, MD • Brigham and Women's Hospital; Boston, MA

At the conclusion of this session participants should be able to:

  • review clinical advances in lupus in 2012
  • discuss drugs in development in 2012-2013
  • identify current gaps in diagnosis and treatment

New Therapies in Rheumatoid Arthritis
Clifton O. Bingham III, MD • Johns Hopkins University; Baltimore, MD

At the conclusion of this session participants should be able to:

  • appropriately utilize the most recently-approved biologic and small molecule therapies for rheumatoid arthritis
  • describe the mechanisms of action and efficacy data of pipeline biologic and small molecule therapies for rheumatoid arthritis
  • evaluate future potential agents for rheumatoid arthritis treatment based on the evolving biology of rheumatoid arthritis

Osteoarthritis: State-of-the-Art and Future Perspectives
Steve B. Abramson, MD • New York University Hospital of Joint Disease; New York, NY

At the conclusion of this session participants should be able to:

  • describe the known mechanisms by which osteoarthritis develops and progresses
  • recognize the role of inflammation in the pathogenesis of  osteoarthritis
  • identify potential biochemical markers that may predict disease progression and how they might facilitate future DMOAD development

10:15 AM
Break

10:45 – 12:15 PM
SESSION II: PAIN

Mechanisms of Musculoskeletal Pain
Roland Staud, MD • University of Florida; Gainesville, FL

At the conclusion of this session participants should be able to:

  • recognize the important role of inflammation for pain
  • distinguish between peripheral and central pain processing in diagnosis and clinical practice
  • recognize factors that modulate chronic pain, and modulate these factors to reduce the likelihood and/or impact of chronic pain in patients with rheumatic diseases

Update on Treatment Options for Low Back Pain
David G. Borenstein, MD • Arthritis & Rheumatism Association; Washington, DC         

At the conclusion of this session participants should be able to:

  • review the common underlying etiologies of low back pain by diagnostic category
  • interpret the literature on efficacy of epidural injections
  • discuss data on efficacy of artificial discs
  • compare non-pharmacologic therapies for low back pain

Pediatric Amplified Pain: When it Is and When it Isn’t
David D. Sherry, MD • Children's Hospital of Philadelphia; Philadelphia, PA

At the conclusion of this session participants should be able to:

  • explain the diagnosis of amplified pain in children
  • list differential diagnostic entities in considering pediatric amplified pain
  • discuss treatment options for amplified pain in children
  • recognize and diagnose conversion

12:15 PM
Boxed Lunch

12:30 – 1:30 PM
Lunch Sessions (Space is limited. Separate registration fees apply unless indicated otherwise.)

Osteoarthritis: The New ACR Guidelines and Current Treatment
Steve B. Abramson, MD • New York University Hospital of Joint Disease; New York, NY

At the conclusion of this session participants should be able to:

  • diagnose and assess the severity of osteoarthritis, including radiographic assessment
  • discuss the evidence for currently available treatments of osteoarthritis
  • apply the new ACR guidelines to optimize the treatment of osteoarthritis in the individual patient

Pediatric Rheumatology for the Adult Rheumatologist
David D. Sherry, MD • Children's Hospital of Philadelphia; Philadelphia, PA

At the conclusion of this session participants should be able to:

  • understand key aspects and pearls of pediatric rheumatology that adult rheumatologists should know

Rehabilitation
Kenneth S. O'Rourke, MD • Wake Forest School of Medicine; Winston-Salem, NC

At the conclusion of this session participants should be able to:

  • discuss available rehabilitative strategies, and their evidence base, for the treatment of patients with selected musculoskeletal conditions
  • incorporate information on rehabilitative strategies into the formation of a therapy prescription

ANCA-Associated Vasculitis
John H. Stone, MD, MPH • Harvard Medical School; Cambridge, MA

At the conclusion of this session participants should be able to:

  • understand current approaches to the induction of remission in ANCA-associated vasculitis
  • gain insight into the impact of both rituximab and cyclophosphamide on B cell kinetics and to appreciate the implications of this for therapy
  • recognize complications of therapies and appreciate means by which these may be avoided

Disease Assessment in Rheumatoid Arthritis
Joan M. Bathon, MD • Columbia University Medical Center; New York, NY

At the conclusion of this session participants should be able to:

  • recognize the importance of disease activity assessment in the management of a patient with rheumatoid arthritis
  • distinguish the utility of disease activity assessment in a treat to target approach
  • distinguish between different tools used in disease activity assessment in patients with rheumatoid arthritis

Pharmacotherapy for the Treatment of Non-renal Lupus
Elena M. Massarotti, MD • Brigham and Women's Hospital; Boston, MA

At the conclusion of this session participants should be able to:

  • list the mechanisms of action, toxicities, and dosing of the immunosuppressive medications used to treat non-renal lupus
  • identify treatment strategies for specific manifestations of non-renal lupus
  • review the evidence based literature that inform these treatment decisions

Practical Approach to Common Low Back Pain Syndromes through Case Vignettes
David G. Borenstein, MD • Arthritis & Rheumatism Association; Washington, DC

At the conclusion of this session participants should be able to:

  • review typical clinical presentations of common low back pain syndromes including spinal stenosis, disc herniation, osteoarthritis and muscle strain
  • discuss management of these syndromes through case examples

Risk Evaluation and Mitigation Strategies (NO FEE)
Allan Gibofsky, MD, JD • Hospital for Special Surgery; New York, NY

European Perspectives: Seronegative Spondyloarthropathies (NO FEE)
Marcello Govoni, MD • University of Ferrara; Ferrara, Italy
Ignazio Olivieri, MD • University of Pisa Medical School; Pisa, Italy

1:45 – 2:15 PM
SESSION III: MUSCLE DISEASE

Myositis
Paul H. Plotz, MD • NIAMS NIH; Bethesda, MD

At the conclusion of this session participants should be able to:

  • discuss the differential diagnosis of a patient presenting with muscle weakness and elevation of the CPK
  • review diagnostic pearls to avoid incorrect diagnosis of myositis
  • analyze treatment options in newly diagnosed and refractory myositis and dermatomyositis

Metabolic Myopathies
Kenneth S. O'Rourke, MD • Wake Forest School of Medicine; Winston-Salem, NC

At the conclusion of this session participants should be able to:

  • discuss the sources of energy for muscle metabolism
  • describe the evaluation of a patient presenting with a suspected metabolic myopathy, correlating defects in energy production pathways with symptoms
  • summarize available therapies for patients with metabolic myopathies

Fellow Case Presentations with Speaker Panel
Kenneth S. O'Rourke, MD • Wake Forest School of Medicine; Winston-Salem, NC
Paul H. Plotz, MD • NIAMS NIH; Bethesda, MD

3:15 PM
Break

3:30 – 5:00 PM
SESSION IV: HOT TOPICS

IgG4-Related Disease
John H. Stone, MD, MPH • Harvard Medical School; Cambridge, MA

At the conclusion of this session participants should be able to:

  • appreciate the breadth of organ system manifestations of IgG4-related disease
  • recognize the ways in which this new rheumatologic condition mimics established rheumatologic conditions
  • gain insight into current treatment approaches for IgG4-related disease and to appreciate what mechanistic studies on this condition can tell us about the immune system

Vaccinations in Patient with Rheumatic Diseases
Clifton O. Bingham III, MD • Johns Hopkins University; Baltimore, MD

At the conclusion of this session participants should be able to:

  • recognize the impact that rheumatic diseases have on the efficacy of various vaccines, and the importance of vaccination in these same patients
  • describe the potential risks of recombinant versus live attenuated vaccines as these apply to specific rheumatic diseases, disease activities and immunosuppressive therapies
  • develop a treatment algorithm for vaccination of rheumatic disease patients, in order to promote optimal vaccine efficacy with minimally possible adverse effects

Cardiovascular Disease in Rheumatoid Arthritis
Joan M. Bathon, MD • Columbia University Medical Center; New York, NY

At the conclusion of this session participants should be able to:

  • elucidate the difference in prevalence/incidence of cardiovascular disease and cardiovascular risk factors in rheumatoid arthritis versus matched controls
  • delineate the effect of rheumatoid arthritis and inflammation on cardiovascular metabolic pathways
  • probe the effect of rheumatoid arthritis treatment on risk of cardiovascular disease in rheumatoid arthritis patients

SUNDAY, APRIL 21, 2013

7:00 AM
Continental Breakfast

7:00 – 8:00 AM
Breakfast Sessions (Space is limited. Separate registration fees apply unless indicated otherwise.)

Interpreting Efficacy Data from Rheumatoid Arthritis RCTs: How should we implement what we learn in routine clinical care?
Yusuf Yazici, MD • New York University Hospital for Joint Diseases; New York, NY

At the conclusion of this session participants should be able to:

  • define a treatment target and implement treat-to-target strategies in rheumatoid arthritis management
  • know how to use and score the various composite indices to assess rheumatoid arthritis disease activity, and be able to identify the optimal outcome measure(s) to apply to specific individual practice settings
  • distinguish between clinically relevant versus merely statistically important changes in the various rheumatoid arthritis disease scales

Pathology: Lupus Nephritis
Anthony Chang, MD • University of Chicago; Chicago, IL

At the conclusion of this session participants should be able to:

  • understand the pathologic findings and classification of lupus nephritis

Politics and Practical Application in the Age of Health Care Reform (NO FEE)
Timothy Laing, MD • University of Michigan Medical Center; Ann Arbor, MI

8:15 – 9:45 AM
SESSION V: OSTEOPOROSIS

Controversy of Treatment: Calcium & Vitamin D
Clifford Rosen, MD • Maine Medical Research Institute; Scarborough, ME

At the conclusion of this session participants should be able to:

  • discuss normal metabolism and handling of Vitamin D
  • understand the literature behind the recommendations for calcium and Vitamin D supplementation
  • review the current data and controversies regarding recommendations for calcium and Vitamin D intake
  • counsel patients on calcium and Vitamin D supplementation for various clinical scenarios including, normal aging, osteoporosis, and diseases requiring steroid therapy

Bisphosphonate Therapy
Michael McClung, MD • Oregon Osteoporosis Center; Portland, OR

At the conclusion of this session participants should be able to:

  • recognize the clinical picture and epidemiology of typical fractures associated with bisphosphonate therapy
  • appreciate the benefit-risk relationship with long-term bisphosphonate therapy
  • review the recent FDA recommendations regarding duration of bisphosphonate use

Audience Discussion with Speaker Panel
Michael McClung, MD • Oregon Osteoporosis Center; Portland, OR
Clifford Rosen, MD • Maine Medical Research Institute; Scarborough, ME

9:45 AM
Break

10:15 – 11:45 AM
SESSION VI: VASCULITIS

Behcet's Syndrome: What It Is, and What It Is Not
Yusuf Yazici, MD • New York University Hospital for Joint Diseases; New York, NY

At the conclusion of this session participants should be able to:

  • identify patients with possible Behcet's syndrome, develop a working differential diagnosis, and make the diagnosis where appropriate
  • know the immunosuppressive approaches most useful in Behcet’s syndrome, and initiate treatment in appropriate patients
  • incorporate knowledge of the natural history of Behcet’s, as well as the role of gender and ethnic/racial background in risk stratification and treatment of the Behcet’s patient

Viral Infectious Arthritis
Leonard Calabrese, DO • Cleveland Clinic Foundation; Cleveland, OH

At the conclusion of this session participants should be able to:

  • understand the microbiology and natural history and epidemiology of viral hepatitis (B and C)
  • comprehend how to order and interpret serologies to detect chronic, persistent, and recovered infection

Central Nervous System Vasculitis
Leonard Calabrese, DO • Cleveland Clinic Foundation; Cleveland, OH

At the conclusion of this session participants should be able to:

  • recognize the clinical and neuroradiographic symptoms of PACNS
  • execute the diagnosis and algorithm for management of PACNS
  • recognize and differentiate disease mimics